Becker-Pelster, Eva M.
Hahn, Michael G.
Delbeck, Martina
Dietz, Lisa
Hüser, Jörg
Kopf, Johannes
Kraemer, Thomas
Marquardt, Tobias
Mondritzki, Thomas
Nagelschmitz, Johannes
Nikkho, Sylvia M.
Pires, Philippe V.
Tinel, Hanna
Weimann, Gerrit
Wunder, Frank
Sandner, Peter
Schuhmacher, Joachim
Stasch, Johannes-Peter
Truebel, Hubert K. F.
Funding for this research was provided by:
Bayer AG
Article History
Received: 6 May 2022
Accepted: 16 September 2022
First Online: 1 October 2022
Declarations
:
: All study procedures conformed to current national legislation (German protection of animals act [2015/07/04], amended 2020/06/19) and the EU directives 63/2010 on the protection of animals used for scientific purposes. All studies were approved by the regional regulatory authority (LANUV NRW, Recklinghausen, Germany) and the institutional animal care office of Bayer AG, Berlin, Germany. Where necessary, animals were sacrificed under anaesthesia upon completion of the experiment by intravenous injection of 4 mL of T61 solution (5 mg tetracaine hydrochloride/50 mg mebezonium iodide/200 mg embutramide per mL).This paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as recommended by funding agencies, publishers, and other organisations engaged with supporting research.
: Not applicable: no data from humans is included in this paper.
: All authors are or were, at the time of the studies, employees of Bayer AG. J-PS, TK, and JS have retired since the studies were conducted.In addition: EMB-P is mentioned as co-inventor on WO2014012934(A1) and on EP21218165.5 pending; FW is mentioned as co-inventor on WO2014012934(A1); MD is mentioned as co-inventor on WO2014012934(A1); JN is mentioned as co-inventor on EP21218165.5 pending; GW is mentioned as co-inventor on EP21218165.5 pending; J-PS is mentioned as co-inventor on WO2014012934(A1); LD is mentioned as co-inventor on EP21218165.5 pending; MGH is mentioned as co-inventor on WO2014012934(A1) and on EP21218165.5 pending.